

TURN YOUR LC INTO A PROTEOFORM METER

PROTEOMETER-L STARTER KIT

The Proteometer Kit transforms any LC with a fluorescence detector into an analytical system capable of identifying and quantifying titer and relative aggregate content in crude culture filtrate in <10 minutes, without sample preparation.

This plug-and-play solution provides savings of over \$200,000 per day by eliminating the hours of sample preparation traditionally required for molecular analysis.¹⁻²

At-line Applications:

- Drug Discovery
- Clone Selection
- High Throughput Screening
- PR&D and Manufacturing

FEATURES & BENEFITS



- Direct analysis from CFF
- Includes all components for titer & aggregate analysis of mAbs
- <10-minute structural analysis
- Allows for multiplexing, unlike traditional ELISA analysis
- Works with existing LCs

KIT COMPONENTS / FEATURES

- Proteometer-L Reactor
- Proteometer-L Reagent
- Proteometer-L Buffer
- Proteometer-L Reconstitution Reagent
- Instructions for use



² JAMA, March 3, 2020; Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018; Olivier J. Wouters, PhD1; Martin McKee, MD, DSc2; Jeroen Luyten, PhD3;; Average cost range, 10 year

SCIENTIFIC BENEFITS

- No sample purification required
- mAb titer and relative aggregate content in one easy-to-use assay
- Linear response from 0.5-80µg mAb (response range may vary per instrument)
- No Mass Spec required



"We use the Proteometer-L Kit for the rapid analysis of mAbs for titer and aggregate content from cell-free filtrate samples. It eliminates sample preparation steps, Protein A purification, and mass spectrometry analysis steps. I would recommend the Proteometer to any pharmaceutical company to quickly and accurately quantitate mAb titer and aggregate content."

> Harsha Gunawardena, Ph.D., Principal Scientist Janssen Pharmaceuticals (Johnson & Johnson's research division)

"Novilytic's Proteometer is a disruptive breakthrough that finally solves the FDA's requirement to continuously monitor t-mAb proteoforms during fermentation. The approach improves product safety, reduces COPQ and post release testing, and paves the way for real-time product release, reducing inventory costs."

> Martin Long, BSc. Performance Validation, Inc. President & CEO



